Research Activity
Stoke Therapeutics Advances Dravet Syndrome Drug to Phase III Trials After FDA Lifts Partial Clinical Hold
Stoke Therapeutics, Dravet syndrome, Phase III trials, FDA, zorevunersen, SCN1A activator, orphan drug designation, rare pediatric disease designation
Actinium to Pursue Additional Clinical Trial for AML Radioactive Drug Following FDA Request
Actinium Pharmaceuticals, AML, radioactive drug, FDA, clinical trial, Iomab-B, SIERRA trial
Bayer’s Kerendia Achieves Primary Endpoint in Phase III Heart Failure Study
Bayer, Kerendia, finerenone, heart failure, cardiovascular outcomes, Phase III study, FINEARTS-HF
Actinium’s Radioconjugate Faces Setback as FDA Requests New Study
Actinium Pharmaceuticals, radioconjugate, FDA, new study, Iomab-B, regulatory affairs, biotech, cancer treatment
MBX Secures $63.5M in Funding Ahead of Clinical Readouts
MBX, clinical readouts, funding, engineered peptide therapeutics, hypoparathyroidism, Phase II trial
Nuvation Bio Halts Development of BET Inhibitor NUV-868 Following Interim Phase 1 Data Review
Nuvation Bio, BET inhibitor, NUV-868, Phase 1 data, oncology drug, safety and efficacy, clinical trials
Galapagos Halts BCMA CAR-T Study Due to Parkinsonism Case
Galapagos, BCMA CAR-T, Parkinsonism, multiple myeloma, CAR-T therapy, clinical trial, PAPILIO-1 study, GLPG5301
Agios’ Pyrukynd Misses Primary Endpoint in First Pediatric Study for Rare Blood Disorder
Agios Pharmaceuticals, Pyrukynd, mitapivat, PK deficiency, pediatric study, blood disorder, Phase 3 ACTIVATE-KidsT study
Vertex Pharmaceuticals Abandons Two Phase I AATD Drug Candidates Due to Disappointing Data
Vertex Pharmaceuticals, AATD, alpha-1 antitrypsin deficiency, drug candidates, Phase I trials, disappointing data
Vir Biotechnology Lays Off 25% of Staff, Shifts Focus to Cancer Research in Sanofi Partnership
Vir Biotechnology, layoffs, Sanofi partnership, cancer research, monoclonal antibodies